Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MindBio Therapeutics Corp C.MBIO

Healthcare Biotechnology Psychedelics
MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its... see more

Recent & Breaking News (CSE:MBIO)

MindBio Announces Arrangements to Address Mailing Delays Resulting from Canada Post Strike

TheNewsWire 12 days ago

MindBio Announces Completion of Private Placement and Issuance of Listed Securities

TheNewsWire December 9, 2024

MindBio Reports a 72% Reduction in Severity of Depression Sustained Six Months After Treatment in Clinical Trials

TheNewsWire October 29, 2024

Mindbio Announces Clinical Trial Milestone In Phase 2B Microdosing Trials Targeting Existential Distress, Depression & Anxiety In Advanced Stage Cancer

TheNewsWire October 24, 2024

MindBio Completes Final Post Treatment Milestone in Phase 2A Microdosing Depression Clinical Trial. Results to be Reported in the Coming Fortnight

TheNewsWire October 22, 2024

MindBio Announces Proposed Issuance of Listed Securities

TheNewsWire October 16, 2024

MindBio Develops Long Term Shelf-Stable Microdosing Formulation and is Progressing in Multiple Phase 2B Clinical Trials

TheNewsWire October 8, 2024

MindBio Therapeutics Enrols 25th Participant into Landmark Take-Home Microdosing Depression Trial

TheNewsWire September 23, 2024

MindBio advances world-first psychedelic microdosing clinical trials

Jonathon Brown August 29, 2024

MindBio CEO Provides Video Update to Shareholders on Progress of World First, Government Approved Microdosing Clinical Trials

TheNewsWire August 29, 2024

MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials

Accesswire August 19, 2024

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

Accesswire August 1, 2024

Mindbio Therapeutics CEO Issues Letter To Shareholders

Accesswire July 8, 2024

MindBio's microdosed LSD reduces depression post treatment

Trevor Abes  June 20, 2024

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

Accesswire June 20, 2024

MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

Accesswire June 12, 2024

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

Business Wire May 14, 2024

MindBio Therapeutics Scientists Present Landmark Women's Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month

Accesswire May 2, 2024

MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3

Accesswire May 1, 2024

MindBio Therapeutics Announces Landmark Women's Health CNS Drug Trials

Accesswire April 30, 2024